[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342053-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342053-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","modeling-lung-adenocarcinoma-metastases-using-patient-derived-organoids","Modeling lung adenocarcinoma metastases using patient-derived organoids","","Approximately half of surgically resected early-stage lung cancer patients develop distant metastasis, yet there is limited in vivo modeling to study the biology of human lung adenocarcinoma (LUAD) metastases. Using well-characterized LUAD patient-derived organoids (PDOs), the study establishes an in vivo metastasis model that preserves human metastatic features. Genomic and RNA sequencing support clonality, tumor evolution, biomarker discovery, therapeutic efficacy testing, resistance mechanisms, and patient-specific immune-priming strategy development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/modeling-lung-adenocarcinoma-metastases-using-patient-derived-organoids/342053/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/modeling-lung-adenocarcinoma-metastases-using-patient-derived-organoids/342053.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address about lung cancer metastasis modeling?","Question",{"text":63,"@type":64},"The work addresses the lack of an in vivo model that can investigate the biology of human lung cancer metastases, particularly for LUAD.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the researchers build the patient-derived organoid (PDO) metastasis model?",{"text":68,"@type":64},"They initiate an LUAD PDO platform using surgically resected primary tumors, malignant pleural effusions, and metastatic LUAD biospecimens, then assess clinicopathologic features to improve PDO generation.",{"name":70,"@type":61,"acceptedAnswer":71},"What can the model be used to test regarding therapies and immunity?",{"text":72,"@type":64},"The model is used to study targeted therapy efficacy and mechanisms of drug resistance, and when cocultured with autologous PBMCs it can help determine optimal immune-priming strategies for individual patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342053,1790193322,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Report  \nModeling lung adenocarcinoma metastases using patient-derived organoids  \nGraphical abstract  \nHighlights  \nAuthors  \nYuan Liu, Manendra Lankadasari, Joel Rosiene, ..., Marty W. Mayo, Marcin Imielinski, David R. Jones  \nCorrespondence  \n[jonesd2@mskcc.org](jonesd2@mskcc.org)  \nIn brief  \nLiu et al. illustrate multiple applications of an in vivo lung adenocarcinoma metastasis model using patient-derived organoids. Applications include the elucidation of the biology of metastases at an individual patient level, discernment of mechanisms of resistance to targeted therapies, and dissection of immunepriming strategies in patient-derived organoids treated with immunotherapy.  \nd Speciﬁc clinicopathologic features of the primary LUAD tumor affect PDO generation  \nd Our in vivo PDO metastasis model is a tool for the study of tumor evolution  \nd Our in vivo PDO metastasis model reveals mechanisms of resistance to targeted therapy  \nd Coculture of PDOs and PBMCs can identify personalized immune-priming strategies  \nLiu et al., 2024, Cell Reports Medicine 5, 101777  \nOctober 15, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101777](https://doi.org/10.1016/j.xcrm.2024.101777)  \nll  \nll  \nOPEN ACCESS  \nReport  \nModeling lung adenocarcinoma metastases using patient-derived organoids  \nYuan Liu,1,2 Manendra Lankadasari,1,2 Joel Rosiene,3 Koﬁ E. Johnson,4,5 Juan Zhou,1,2 Samhita Bapat,1,2 Lai-Fong L. Chow-Tsang,1,2 Huasong Tian,3 Brooke Mastrogiacomo,1,2,6 Di He,1,2 James G. Connolly,1,2 Harry B. Lengel,1,2 Raul Caso,1,2 Elizabeth G. Dunne,1,2 Cameron N. Fick,1,2 Gaetano Rocco,1,2 Smita Sihag,1,2 James M. Isbell,1,2 Mathew J. Bott,1,2 Bob T. Li,2,7 Piro Lito,2,7 Cameron W. Brennan,8 Mark H. Bilsky,8  \nNatasha Rekhtman,2,9 Prasad S. Adusumilli,1,2 Marty W. Mayo,10 Marcin Imielinski,3 and David R. Jones1,2,11,12,13,*  \n1Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n2Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n3Department of Pathology, New York University, New York, NY, USA  \n4Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA  \n5Tri-Institutional PhD Program in Computational Biology and Medicine, New York, NY, USA  \n6Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n8Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n9Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n10Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA  \n11X (formerly Twitter): @JonesDavid2013  \n12X (formerly Twitter): @MSK_Thoracic  \n13Lead contact  \n*Correspondence: [jonesd2@mskcc.org](jonesd2@mskcc.org)  \n[https://doi.org/10.1016/j.xcrm.2024.101777](https://doi.org/10.1016/j.xcrm.2024.101777)  \nSUMMARY  \nApproximately 50% of patients with surgically resected early-stage lung cancer develop distant metastasis. At present, there is no in vivo metastasis model to investigate the biology of human lung cancer metastases. Using well-characterized lung adenocarcinoma (LUAD) patient-derived organoids (PDOs), we establish an in vivo metastasis model that preserves the biologic features of human metastases. Results of wholegenome and RNA sequencing establish that our in vivo PDO metastasis model can be used to study clonality and tumor evolution and to identify biomarkers related to organotropism. Investigation of the response of KRASG12C PDOs to sotorasib demonstrates that the model can examine the efﬁcacy of treatments to suppress metastasis and identify mechanisms of drug resistance. Finally, our PDO model cocultured with autologous peripheral blood mononuclear cells can potentially be used t","cbCaihLJ3n00Ymsr","https://ap.wps.com/l/cbCaihLJ3n00Ymsr","pdf",7750005,18,"English","# Summary\n# Introduction\n# Methods and model development\n# Genomics, clonality, and evolution\n# Therapeutic response and resistance\n# Immune co-culture and immune-priming strategies","[{\"question\":\"What problem does the study address about lung cancer metastasis modeling?\",\"answer\":\"The work addresses the lack of an in vivo model that can investigate the biology of human lung cancer metastases, particularly for LUAD.\"},{\"question\":\"How do the researchers build the patient-derived organoid (PDO) metastasis model?\",\"answer\":\"They initiate an LUAD PDO platform using surgically resected primary tumors, malignant pleural effusions, and metastatic LUAD biospecimens, then assess clinicopathologic features to improve PDO generation.\"},{\"question\":\"What can the model be used to test regarding therapies and immunity?\",\"answer\":\"The model is used to study targeted therapy efficacy and mechanisms of drug resistance, and when cocultured with autologous PBMCs it can help determine optimal immune-priming strategies for individual patients.\"}]","Modeling lung adenocarcinoma metastases using patient-derived organoids | PDF",1790044917,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f35704ce7ee9604ff52e1f02358e56b.webp",983,1276,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ea00d37c7ac05483f3ab992fd52db56.webp",982,1275,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7d1dcf1771a79d4403980394d88679f.webp",981,1273,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1206f80fbd4ec0ed91274203870af66b.webp",980,1272]